(Q43004356)

12 November 2017

title

Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis (English)

1 reference

12 November 2017

T Lee

1

1 reference

12 November 2017

K-H Oh

2

1 reference

12 November 2017

K W Joo

3

1 reference

12 November 2017

Y S Kim

4

1 reference

12 November 2017

C Ahn

5

1 reference

12 November 2017

J S Han

6

1 reference

12 November 2017

S Kim

7

1 reference

12 November 2017

H J Chin

8

1 reference

12 November 2017

publication date

1 July 2010

1 reference

12 November 2017

1 reference

12 November 2017

volume

19

1 reference

12 November 2017

issue

8

1 reference

12 November 2017

page(s)

974-980

1 reference

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Value of a complete or partial remission in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Therapeutic options for resistant lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

21 January 2018

Lupus nephritis flares

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Successful treatment of class V+IV lupus nephritis with multitarget therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

Increased drug delivery to the brain by P-glycoprotein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203310366573

21 January 2018

Identifiers

DOI

10.1177/0961203310366573

1 reference

12 November 2017

1 reference